RxDoctor Payments Data

Andreas Mauer, MD

Interventional Cardiology · Pasadena, CANPI 1477739597

Payments from drug & device makers

$132,669in general payments, 2019–2025

Across 624 payments — averaging $212.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$118K
  • Amgen$2K
  • Edwards Lifesciences$2K
  • Novartis$1K
  • Abbott$1K
  • Pfizer$1K
  • plus $7K from 35 others

What the payments were for

  • Food & beverage$14,613100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$132,669 in reported general payments places this provider in the 80th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$710,542
Medicare patients
2,381
Services billed
7,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban671$685,645
VyndamaxTafamidis11$288,702
EntrestoSacubitril/Valsartan248$238,849
FarxigaDapagliflozin Propanediol149$123,803
XareltoRivaroxaban95$85,484
JardianceEmpagliflozin90$70,300
Repatha SureclickEvolocumab81$69,922
MultaqDronedarone Hcl34$36,859
NexlizetBempedoic Acid/Ezetimibe38$23,402
InpefaSotagliflozin16$9,374
Metoprolol Succinate547$7,282
ZetiaEzetimibe15$5,849
Atorvastatin Calcium539$5,697
Amiodarone Hcl95$5,159
Rosuvastatin Calcium229$3,944

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$1,276$974,347682 claims
NovartisEntresto$1,352$238,849248 claims
AstraZenecaFarxiga$834$123,803149 claims
Johnson & JohnsonXarelto$285$85,48495 claims
Boehringer IngelheimJardiance$335$70,30090 claims
Sanofi-aventis U.S. LLCMultaq$131$36,85934 claims
Esperion Therapeutics, Inc.Nexlizet$216$23,40238 claims
Lexicon Pharmaceuticals, Inc.Inpefa$241$9,37416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →